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Alzheimer’s (AD) and Parkinson’s (PD) diseases are the two most common causes of dementia in aged population. Both are
protein-misfoldingdiseasescharacterizedbythepresenceofproteindepositsinthebrain.Despitegrowingevidencesuggestingthat
oxidative stress is critical to neuronal death, its precise role in disease etiology and progression has not yet been fully understood.
Budding yeast Saccharomyces cerevisiae shares conserved biological processes with all eukaryotic cells, including neurons. This
fact together with the possibility of simple and quick genetic manipulation highlights this organism as a valuable tool to unravel
complex and fundamental mechanisms underlying neurodegeneration. In this paper, we summarize the latest knowledge on the
role of oxidative stress in neurodegenerative disorders, with emphasis on AD and PD. Additionally, we provide an overview of the
work undertaken to study AD and PD in yeast, focusing the use of this model to understand the eﬀect of oxidative stress in both
diseases.
1.Introduction
Misfolded proteins are typically insoluble and tend to form
long linear or ﬁbrillar aggregates known as amyloid deposits.
Amyloid-like protein ﬁbrils are a well-known pathological
hallmark of age-related neurodegenerative diseases, includ-
ing Alzheimer’s disease (AD) and Parkinson’s disease (PD).
Alzheimer’s and Parkinson’s diseases are the most common
forms of dementia, currently aﬀecting 30 and 4 million
peopleworldwide,respectively.InAD,thebeta-amyloid(Aβ)
peptide accumulates mainly extracellularly, whereas in PD,
the α-Synuclein (α-Syn) protein accumulates, within neu-
rons, inside the Lewy bodies (LB) and Lewy neurites (LN).
Although there is a plethora of factors interfering in those
pathological depositions, it is clear that oxidative stress may
play a crucial role in neuronal death in neurodegenerative
disorders [1–3].
Reactive oxygen species (ROS) are chemically reactive
molecules containing oxygen and are produced in all aerobic
cells. Oxidative stress occurs when the generation of ROS
in a system exceeds that system’s ability to neutralize and
to eliminate them. All organisms have developed adaptive
responses to oxidative stress that involve defensive enzyme
and molecular chaperones—the expression of both being
orchestrated by stress-responsive transcription factors—as
well as antioxidant molecules [4]. Excessive production
of ROS, and the consequent disruption of cellular redox
balance, drives the oxidation of biological macromolecules,
such as DNA, proteins, carbohydrates, and lipids, potentially
leading to failure of biological functions [4].
Many ROS possess unpaired electrons and are therefore
free radicals. The generation of free radicals is closely
linked with the involvement of trace metals, particularly
copper and irons [5, 6]. To cope with this potential hazard,
the concentration of cytosolic free metals is accurately
controlled through regulation of their uptake, storage, and
mobilization, in order to maintain redox-active metals in
normal physiological limits [7, 8]. Inside cells, “free pools” of
copper and iron are avoided through their eﬀective sequester
by metal-binding proteins [5, 9]. The chelatable redox-active2 Oxidative Medicine and Cellular Longevity
iron constitutes the so-called labile iron pool (LIP), which
serves as a transient source of iron [5, 9, 10]. Nevertheless,
whenever cells are subjected to stress conditions, an excess of
superoxide anion radical acts as an oxidant of Fe-S clusters of
several enzymes, releasing “free iron.” The released iron can
in turn participate in Fenton type reactions, producing the
highly reactive hydroxyl radical [11].
During the oxidative burst triggered during inﬂamma-
tory processes, cells of the immune system produce both
superoxide anion and nitric oxide (NO) free radicals. Nitric
oxide is produced by the NO synthase family of enzymes.
NO may directly react with its biological targets, as it is
known to regulate the catalytic activity of various enzymes
primarily by interacting with Fe-S clusters, oxidized copper
centres, heme, and tyrosyl radicals [12]. NO also reacts with
superoxide ion (O2
−) or oxygen to form the nitrogen radical
peroxynitrite(ONOO
−).Reactivenitrogenspecies(RNS)are
highly reactive towards biological macromolecules and are
thought to be responsible for NO-mediated cell death.
The aim of this paper is to provide an overview on
the role of oxidative stress in neurodegenerative disorders,
with emphasis on AD and PD. Despite the absence of a
nervous system in yeast, several studies have shown that this
eukaryotic unicellular organism is a suitable model system
to understand the molecular mechanisms underlying neu-
rodegenerative diseases. The knowledge from those studies
is summarized herein. Finally, we discuss how yeast models
have been or may be used to extend our understanding on
the role of oxidative stress in AD and PD.
2. OxidativeStressand
Neurodegenerative Diseases
The human brain is responsible for approximately 20% of
our body oxygen consumption and thus subjected to a high
metabolically derived level of ROS [13, 14]. An increasing
body of evidence suggests that oxidative stress is involved
in the etiology and pathogenesis of neurological disorders.
The lipid bilayer of the brain is rich in polyunsaturated
fatty acids and oxygen and is therefore highly susceptible
to lipid peroxidation, a complex process involving the
interaction of polyunsaturated fatty acids with free radicals
that results in production of reactive electrophilic aldehy-
des. Lipid peroxidation occurs in several neurodegenerative
diseases [15]. Evidence of oxidative stress in these diseases
is further supported by increased DNA (and often RNA)
base oxidation products and oxidative protein damages in
speciﬁc regions of the brain [4]. The destruction of cellular
components can induce a diversity of cellular responses
through generation of secondary reactive species and ulti-
mately lead to cell death via apoptosis and necrosis [16–
18]. Mitochondrion is the center of ROS production. About
90% of mammalian oxygen consumption is mitochondrial,
making mitochondria particularly important in neurons
due to their high demands for energy. This fact, together
with the observation that mitochondrial perturbation occurs
in multiple neurodegenerative disorders [19], suggests that
neurodegenerative diseases are mitochondrial diseases.
3. Alzheimer’s Disease andOxidativeStress
Alzheimer’s disease (AD) is an age-related progressive neu-
rodegenerative disease caused by severe neurodegeneration
in the hippocampus and neocortical regions of the brain of
aﬀected individuals [20].
AD pathological hallmarks include extracellular amyloid
plaquesandintracellularaggregates(neuroﬁbrillarytangles).
The major component of the amyloid plaques is the amyloid
peptideAβ, which results from the proteolysis of the amyloid
precursor protein (APP). APP is a ubiquitously expressed
transmembrane protein exerting a critical role in neuron
growth and survival [21, 22]. APP proteolysis to form the
Aβ peptide involves the sequential action of aspartic protease
BACE1 (β-secretase) and of γ-secretase, a multiprotein
complex [23]. The length of Aβ peptide may range from
39 to 43 aminoacid residues, due to diﬀerent γ-secretase
cleavagesites.Aβappearstobeunfolded,underphysiological
conditions [24]. In amyloid plaques, the most frequent
species are Aβ40 and Aβ42, the latter being the most prone
to aggregation [23]. Neuroﬁbrillary tangles are composed
of hyperphosphorylated tau protein, a microtubule-binding
protein thought to be involved in microtubules stabilization
and in regulation of axonal transport in the brain [25].
The causes of Alzheimer’s disease are not well under-
stood, except for a small percentage of cases that are linked
to familial genetic mutations [26]. Several hypotheses have
been put forward with the aim to explain the cause of the
sporadic form of the disease. One widely discussed of those
hypotheses assumes that amyloid deposits of Aβ peptides are
t h ec a u s a t i v ea g e n t so fA D[ 27]. The “amyloid” theory is
further supported by the link between mutations in the APP
gene and some inherited forms of the disease [26].
Aβ toxicity is dependent on Aβ’s conformational state,
peptide length, and concentration [28, 29]. Moreover, it has
been described that Aβ toxicity is also related to Aβ’s ability
to form hydrogen peroxide and free radicals [30, 31]. These
ﬁndings are supported by the signiﬁcant lipid peroxidation,
proteinoxidation,andDNAoxidationobservedinADbrains
[29, 32, 33]. In addition, two factors reinforce the role of
oxidativestressinADpathogenesis:pro-oxidantsincreaseAβ
production, whereas several antioxidants, namely vitamin E,
melatonin, and several free radical scavengers, can protect
neurons from Aβ-induced toxicity [34].
Interestingly, the Aβ peptide is not toxic in the absence
of redox metal ions, and many recent studies implicate
biometals in the development or progression of Alzheimer’s
disease [6, 35–37]. Accordingly, sophisticated techniques
have shown an overaccumulation of copper, iron, and zinc
within the amyloid plaques compared with the surrounding
tissues [38]. Aβ has high aﬃnity for redox-active metals
being able to reduce them and consequently lead to the
formation of hydrogen peroxide and oxidized amyloid [6].
Butterﬁeld and Bush proposed that a single methionine
residue (Met35) of Aβ42 is critical for the oxidative andOxidative Medicine and Cellular Longevity 3
neurotoxic properties of this peptide [39, 40]. Substitution
of Met35 renders the Aβ peptide nonoxidative and nonneu-
rotoxic [40].ThesulphuratomofMet35ishighlysusceptible
tooxidation,formingthesulﬁderadicalMetS￿+ andreducing
copper(II) to its high-active low-valency form [5, 40]. The
MetS￿+ radical is able to undergo very fast reactions with
superoxide ion, leading to the formation of methionine
sulfoxide (MetO). In AD senile plaques, a signiﬁcant fraction
of Aβ has Met35 in the form of MetO [41].
Another well-studied source of oxidative stress in AD
is mitochondria damage and its consequent functional
abnormality that favors the production of ROS. Indeed,
it was shown that neurons in AD exhibit a signiﬁcantly
higher percentage of damaged mitochondria compared to
an aged-matched group [42]. Furthermore, mitochondrial
dysfunction has been widely implicated in the etiology
of AD, since early impairments of mitochondrial function
and oxidative stress may precede Aβ overproduction and
deposition [43]. Also inﬂammation can induce oxidative
damage in AD, especially via microglia, leading to increased
ROS and RNS formation and the resulting damage to lipid,
proteins, and nucleic acids [44–46].
4. Parkinson’sDisease andOxidativeStress
Parkinson’s disease is an age-related neurodegenerative dis-
order aﬀecting the central nervous system. It is characterized
by the progressive degeneration of nigrostriatal dopamin-
ergic neurons within the substantia nigra pars compacta,
which is the pathological process responsible for the motor
symptoms attributed to PD [47]. The pathological hallmark
of the disease is the presence of proteinaceous cytoplasmic
inclusions designated as Lewy bodies and Lewy neurites.
These are predominantly composed of the presynaptic
protein α-Synuclein (α-Syn) [48] together with proteasomal
andlysosomalsubunitsaswellasmolecularchaperones[49].
The ubiquitous α-Syn brain protein is implicated in both
hereditary and sporadic PD. Its encoding gene, SNCA, was
the ﬁrst genetic determinant associated with the disease
and, for this reason, much of the work on PD converges
on α-Syn [50]. α-Syn was shown to interact with lipids
and membranes, accelerating amyloid ﬁbril formation [51],
and it has been proposed to regulate the dynamics of
synaptic vesicles at the synapse [52]. Indeed, α-Syn exhibits
a remarkable conformational plasticity being its structure
largely dependent on the surrounding environment. The
monomeric α-Syn is a typical natively unfolded protein
under physiological conditions [53, 54]. However, under
speciﬁc conditions, such as the increase of its intracellular
levels, α-Syn can adopt diﬀerent conformations, including
several α-helical and β-sheet species folded to diﬀerent
degrees in both monomeric and oligomeric states [55].
Although PD is a recognized multifactorial disease, a
large body of evidence has implicated oxidative stress in the
pathogenesis of PD. The conclusive connection between PD
and oxidative stress is supported by the increased oxidative
damageofsugars,lipids,nucleicacids,andproteinsobserved
in postmortem dopaminergic neurons within the substantia
nigra pars compacta of PD brains [6, 56, 57].
Auluck et al. proposed that the impairment of α-
Syn function leads to its local accumulation, favoring the
formation of toxic oligomeric species that interfere with
ER-to-Golgi traﬃcking, mitochondria turnover—through
the abrogation of mitophagy—and generate oxidative stress.
Moreover, the abnormal interaction of α-Syn with mem-
branes has been implicated in the cytoplasmic retention
of catecholaminergic neurotransmitters yielding cytotoxicity
through the generation of dopamine adducts and ROS
[52]. This eﬀect is potentiated in the presence of iron-rich
environments, as it is the case of Lewis bodies in the neurons
decorating the substantia nigra of PD patients [58–61].
Indeed, it is known that dopamine is able to coordinate iron
andregenerateFe2+,possiblyprovidinganequallyimportant
source of hydroxyl radical production [62].
Mitochondria have been claimed as dominant sites for
oxidative stress-driven initiation and propagation in PD. The
direct implication of this organelle in PD was ﬁrst suggested
by the use of the mitochondrial complex I (CI) inhibitor
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) [63,
64]. This chemical mimics human PD in animal models and
is associated with development of Parkinsonism in humans
subjected to accidental exposure [65]. Further corroborating
the relevance of mitochondria in PD, it was shown that
the well-known CI inhibitor rotenone induces death of
dopaminergic cells [66–69]. In addition, depletion of the
antioxidant peptide glutathione (GSH) in PD cells, which
may be caused by a decrease in its synthesis and recycling
[70], has been associated with a decrease of mitochondrial
CI activity, resulting in mitochondrial dysfunction [71, 72].
Moreover, defective mitochondrial CI function is observed
in the substantia nigra of PD brains [73, 74]. Recent studies
have also demonstrated thatα-Syn monomers and oligomers
associate with the inner mitochondrial membrane where
they can physically associate with CI, thereby interfering
with the mitochondrial function and increasing free radicals
production [72, 75]. Further highlighting the relevance
of mitochondrial dysfunction and oxidative stress in the
pathological process of the disease, several genes associated
with familial cases of PD were shown to encode either mito-
chondrial proteins or mitochondria-associated proteins [6,
76]. Among the latter is DJ-1, a protein that shares structural
homology with the Escherichia coli chaperone Hsp31 and
is thought to have a protective role against oxidative stress
[77]. Under conditions of oxidative stress, DJ-1 is relocated
to the mitochondria, aﬀecting the sensitivity of speciﬁc
neuron populations to compounds targeting mitochondrial
CI, namely, rotenone, paraquat, and MPTP [6, 78–80].
Several evidences support as well an unbalanced genera-
tion of RNS as a feature of PD pathology. First, nitrated α-
Syn accumulates in LB of PD cells. Secondly, the treatment
of GSH-depleted dopaminergic cells with RNS inhibitors
prevents mitochondrial CI inhibition [6], indicating that
RNS itself has a role in mitochondrial dysfunction and ROS
generation in PD. Lastly, glial cells within the substantia
nigra exhibit increased NO levels [81], possibly due to the
accumulation of interferon-γ (IFN-γ)[ 82], a cytokine which
was shown to promote induction of RNS in brain.4 Oxidative Medicine and Cellular Longevity
5.S. cerevisiae asModelOrganismto
Study Neurodegenerative Diseases
Budding yeast Saccharomyces cerevisiae has been introduced
as an experimental organism in the midthirties of the 20
century. Since then, its potential as a model organism has
been exploited in many areas of biology [83]. Despite lacking
the physiological complexity of the mammalian nervous
system, yeast was recently used in the study of neurode-
generative disorders, such as Alzheimer’s and Parkinson’s
Diseases. This became possible due to the development of
p o w e r f u ly e a s tg e n e t i ct o o l sa sw e l la st h eh i g hc o n s e r v a t i o n
of fundamental biological processes and pathways associated
with neurodegeneration including protein folding, cellular
traﬃcking, and secretion [84]. It is noteworthy that about
one-ﬁfth of yeast genes are members of orthologous gene
families associated with human diseases [85]. This is an
important aspect to consider when studying human diseases
in yeast. If a homologue of the gene implicated in the disease
is present in yeast genome, a unique opportunity to directly
study its function is oﬀered, either through its deletion
or overexpression. Otherwise, if the disease-associated gene
does not have a yeast counterpart, functional analysis can
still be performed via heterologous expression [86, 87].
Equally important “humanized” yeasts are being used as
platforms for high-throughput screenings of compounds
with therapeutic potential.
6. Yeast as a Model for
StudyingAlzheimer’s Disease
Yeast models have been extensively used to study several
molecular aspects of AD, even though yeast lacks for some
AD-associated genes. Studies in yeast have been mainly
focused on the in vivo APP processing, Aβ oligomerization,
and toxicity.
The usage of heterologous expression of human secre-
tases in yeast has greatly contributed to the understanding
of human APP processing. It has allowed the discovery of
BACE1 inhibitors and prompted the study of the individual
function of each component of the γ-secretase complex [88].
Growing evidence suggests that the oligomeric forms of
the Aβ peptide, rather than amyloid ﬁbrils, are the most
toxic forms [89–92]. These ﬁndings have shifted the focus of
investigation towards the earliest stages of Aβ oligomeriza-
tion. As a result, the following described yeast systems were
developed and are now useful tools not only in the study
of Aβ-oligomerization, but also in the understanding of the
molecular events triggered by aggregation as well as in the
screening of potential therapeutic compounds that aﬀect the
aggregation process.
The ﬁrst yeast study on Aβ oligomerization used a two-
hybridapproachtoanalyzeAβ dimerization.Protein-protein
interactions were measured by fusing the Aβ peptide to a
LexADNA-bindingdomainandalsotoaB42transactivation
domain, and then monitoring the expression of a lacZ
reporter driven by a LexA-dependent promoter [93]. The
authors showed that Aβ peptide was able to form dimers, in
vivo, in the yeast cell nucleus.
Bagriantsev and Liebman and von der Haar et al.
implemented a diﬀerent yeast model system that may
constitute a valuable tool to seek for agents that interfere
with the initial steps of Aβ42 oligomerization [94, 95]. In
this study, the ability of Aβ42 peptide to aggregate was
monitored by fusing it to the middle and C-terminal domain
of Sup35. The Sup35 yeast translational termination factor
can undergo spontaneous conversion into a prion state,
losing its function [96]. Sup35 loses the ability to aggregate
when its prion-forming (N-terminal) domain is deleted.
However, the insertion of Aβ peptide sequences in place
of the original prion domain of Sup35 protein restores its
abilitytoaggregate[94,95].Usingthisreportersystem,itwas
possible to conﬁrm in vivo the impact of point mutations,
previously shown to inhibit Aβ42 aggregation in vitro [94,
97]. Furthermore, it was shown that the Hsp104 yeast
chaperone, a chaperone known to rescue proteins from the
aggregated state in other yeast models of neurodegenerative
diseases [98, 99], appears to have a contrary function in
AD, protecting Aβ-fusion protein from disaggregation and
degradation [94, 95].
Oligomerization of Aβ was also the subject of a third
yeaststudy,bytheuseofareporterconsistingofAβ fragment
fused to GFP [100]. The assay was based on the premise
that aggregates of the fusion protein suppressed green ﬂu-
orescence. The Aβ-GFP fusion was shown to cause slight but
signiﬁcantyeastgrowthreductionandtoinduceaheatshock
response (HSR), as indicated by the cotransformation of
y eastwithAβ-GFPandHSE2elementfusedtoadownstream
lacZ gene. The authors put forward the hypothesis that HSR
could arise from Aβ inducing ROS and/or the presence of
misfolded proteins and suggested that HSR might be a target
for further studies seeking for inhibitors of Aβ eﬀects [100].
Recently, Treusch et al. engineered a yeast model for
studyingAβ toxicity [101].Theoverexpressionofaconstruct
harboring the Aβ42 fragment fused at the N-terminus to an
endoplasmatic reticulum targeting sequence was driven by
a galactose-inducible promoter. Aβ oligomers localized to
secretory compartments and, like in neurons, contributed
to toxicity in yeast. A screen for genetic modiﬁers allowed
the identiﬁcation of 40 genes that were able to modulate
Aβ toxicity. Among those, 12 had homologues in humans,
3 being related to clathrin-mediated endocytosis, and 7
functionally associated with the cytoskeleton. Interestingly,
all the former genes behaved as Aβ toxicity suppressors and
had been previously shown to be or interact with validated
risk factors for AD. The authors further showed that Aβ
aﬀects clathrin-mediated endocytosis and proposed that Aβ
oligomers may interact with transmembranar receptors and
prevent their correct destination [101].
7. Yeast as a Model for
StudyingParkinson’s Disease
As a common feature of sporadic and familial cases of PD,
the understanding of the pathological processes associated
with α-Syn has attracted special attention. In order to gain
insight into α-Syn pathobiology, Outeiro and LindquistOxidative Medicine and Cellular Longevity 5
exploited a myriad of advantages of using S. cerevisiae as
a model organism, by developing a powerful “humanized”
yeast system. As a means to study the α-Syn dynamics in
vivo, the authors overexpressed in yeast cells a construct
harboring the wild type or the mutant versions of human
SNCA gene fused to GFP [102]. This pioneering system
faithfully reproduces several features of PD in yeast, allowing
to thoroughly investigate the pathological processes involved
in the disease. Three strains, designated as NonTox, InTox,
and HiTox, were created to express α-Syn at diﬀerent
levels [52]. As it happens in complex eukaryotic models,
the appearance of cytoplasmic foci, cytotoxicity, and α-
Syn-decorated vesicle accumulation was shown to be dose
dependent [102, 103]. Moreover, high doses of α-Syn lead
to increased toxicity, accumulation of cytoplasmic lipid
droplets, vesicle traﬃcking defects, ER stress, activation
of the heat-shock response, impairment of the ubiquitin-
proteasome pathway, and mitochondrial dysfunction in
the HiTox strain, therefore recapitulating the pathological
features displayed by PD patients whose genome encodes
duplications or triplications of SNCA locus [52].
The α-Syn yeast model developed by Outeiro and
Lindquist has been the basis of several genome wide and
high-throughput analyses aimed at unveiling the intricacies
of PD. The systematic screening of a galactose-inducible
overexpression library in the InTox strain revealed the
Rab GTPase Ypt1 (Rab1) as suppressor of α-Syn toxicity
[104], reinforcing the role of α-Syn in vesicle formation
and delivery. In addition, an unbiased genome-wide screen
for modiﬁers of α-Syn toxicity was performed in the
InTox strain, allowing the identiﬁcation of the polyamine
transporter Tpo4 [105] and highlighting the signiﬁcance of
polyamine pathway in PD pathogenesis. Using the Respon-
seNet algorithm to integrate α-Syn mRNA proﬁling and
genome-wide genetic data, it was found that trehalose might
be involved in the protection pathway against α-Syn toxicity
possibly promoting misfolded protein clearance. In addition,
mitochondrial dysfunction and oxidative/nitrosative stress
also appeared as consequences of α-Syn overexpression in
yeast [106]. Comparison of the transcriptome of HiTox and
NonTox strains provides further evidence supporting the
assumption that mitochondrial dysfunction and oxidative
stressareassociatedtoconditionsinwhichα-Synisexpressed
at high levels. It has also been veriﬁed that mitochondria
morphology is aﬀect eda n dR O Si sac c u m u l a t edi nt h eH i T o x
strain further suggesting that high levels of α-Syn elicit
global mitochondrial dysfunction [107]. This may suggest
that α-Syn accumulation is the origin of oxidative damage
of speciﬁc neuronal cells in PD.
More recently, overexpression of α-Syn in yeast revealed
that the knockout of genes encoding lipid elongases, namely,
ELO1, ELO2, and ELO3, impairs cell growth, dramatically
decreases the survival of aged cells, and leads also to ROS
accumulation and aberrant protein traﬃcking [108]. A
similar strategy, using a diﬀerent plasmid to drive galactose-
inducible α-Syn expression in distinct S. cerevisiae back-
grounds, disclosed the signiﬁcance of fatty acid synthase
activity and intracellular redox status in the mechanisms of
α-Syn toxicity [109].
α-Syn-humanized yeasts have also been exploited to
search for compounds with therapeutic potential. In this
context, the HiTox strain was used in a high-throughput
chemical screen to identify agents capable of rescuing the
robust toxicity of this strain. A class of small molecules of
1,2,3,4-tetrahydroquinolinoneswereidentiﬁedandshownto
revert the formation of α-Syn foci, to reestablish ER-to-Golgi
traﬃcking,toamelioratemitochondriadamage,tolimitROS
production, and consequently to reduce α-Syn toxicity not
only in yeast but also in other more complex PD models
[107].
8. Concluding Remarks
Although AD and PD have been extensively studied, the
exact mechanism of disease progression or pathogenesis
remains largely unknown. As outlined in this paper, several
in vivo and in vitro studies point towards a role of oxidative
stress in AD and PD pathogenesis. Nevertheless, whether
it is a primary cause or simply a consequence of the
neurodegenerative process is still an unanswered question.
In addition, speciﬁcally concerning AD, there are quite a few
contradictory reports regarding the role of oxidative stress
in the disease. Indeed, it has been described that oxidative
stress may as well lead to an increase in Aβ [14, 110], and in
vivo studies showed a negative correlation between oxidative
stress and Aβ, indicating an antioxidant role for Aβ [111].
Yeast can be a powerful tool as a means to clarify several
of these issues. Within this context, yeast models of AD may
in the future be used to monitor Aβ oligomerization and
toxicity under an oxidative environment or in the absence
of ROS (hypoxia). Interestingly, a yeast model consisting
of Aβ peptide fused to GFP has been successfully used to
test whether folate, an antioxidant, was able to prevent Aβ
aggregation [112]. To better understand the relationship
between oxidative stress and α-Syn aggregation, in the
pathological processes triggering PD, it would be interesting
to assess both the behavior of α-Syn in the “humanized”
NonTox strain under oxidative environments and in the
InTox and HiTox strains under hypoxia conditions.
FuturestudiescombiningyeastandanimalmodelsofAD
and PD will certainly provide valuable insights into the role
of oxidative stress in these neurodegenerative diseases.
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